Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients

Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients

Background and objectiveDimethyl fumarate (DMF) is an immunomodulatory drug approved for the therapy of multiple sclerosis (MS). The identification of response biomarkers to DMF is a necessity in the clinical practice. With this aim, we studied the immunophenotypic and transcriptomic changes produce...

Full description

Bibliographic Details
Main Authors: Alicia Sánchez-Sanz, Santiago García-Martín, Julia Sabín-Muñoz, Irene Moreno-Torres, Víctor Elvira, Fátima Al-Shahrour, Aranzazu García-Grande, Elvira Ramil, Ofir Rodríguez-De la Fuente, Beatriz Brea-Álvarez, Ruth García-Hernández, Antonio García-Merino, Antonio José Sánchez-López
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
dimethyl fumarate
biomarker
immunophenotype
transcriptome
disease-modifying therapies
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1209923/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1209923/full

Similar Items